Literature DB >> 15312814

Chronic very low dose naltrexone administration attenuates opioid withdrawal expression.

Paolo Mannelli1, Edward Gottheil, James F Peoples, Veronica C Oropeza, Elisabeth J Van Bockstaele.   

Abstract

BACKGROUND: Different regimens of agonist and antagonist drugs have been used in opioid withdrawal management, with variable results. We examined whether administering extremely small quantities of opiate antagonists in the presence of opiate agonist drugs reduces withdrawal expression.
METHODS: Forty-one male Sprague-Dawley rats were implanted with morphine or placebo pellets for eight days. Starting on day 3, some rats received naltrexone in their drinking water (5 mg/L), or unadulterated water. On day 8, rats were injected with saline or naltrexone (100 mg/kg) and evaluated for behavioral signs of withdrawal. Next, sections through the locus coeruleus (LC) and nucleus of the solitary tract (NTS), brainstem areas exhibiting cellular activation following opiate withdrawal, were processed for c-Fos to detect early gene expression. Finally, the same nuclei were examined for protein kinase A regulatory subunit II (PKA) and phosphorylated cyclic adenosine monophosphate response element binding protein (pCREB), using Western blot analysis.
RESULTS: Withdrawal was attenuated and c-Fos, PKA, and pCREB expression was decreased in the NTS and LC of rats receiving chronic very low doses of naltrexone.
CONCLUSIONS: Reduction of withdrawal upon chronic very low naltrexone administration may be due in part to decreased activation of brainstem noradrenergic neurons in morphine dependent rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312814     DOI: 10.1016/j.biopsych.2004.05.013

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  13 in total

1.  Problem drinking and low-dose naltrexone-assisted opioid detoxification.

Authors:  Paolo Mannelli; Kathleen Peindl; Ashwin A Patkar; Li-Tzy Wu; Haresh M Tharwani; David A Gorelick
Journal:  J Stud Alcohol Drugs       Date:  2011-05       Impact factor: 2.582

Review 2.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

3.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

4.  Smoking and opioid detoxification: behavioral changes and response to treatment.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; David A Gorelick
Journal:  Nicotine Tob Res       Date:  2013-04-09       Impact factor: 4.244

5.  Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Authors:  Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2017-01-10       Impact factor: 18.112

6.  The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.

Authors:  Paolo Mannelli; Kathleen Peindl; Li-Tzy Wu; Ashwin A Patkar; David A Gorelick
Journal:  Am J Drug Alcohol Abuse       Date:  2012-01-10       Impact factor: 3.829

7.  Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain.

Authors:  Elisabeth J Van Bockstaele; Yaping Qian; Robert C Sterling; Michelle E Page
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-03-25       Impact factor: 5.067

8.  Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety.

Authors:  Reza Afshari; Majid Khadem-Rezaiyan; Hoda Khatibi Moghadam; Mahdi Talebi
Journal:  Toxicol Res       Date:  2019-11-21

9.  Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.

Authors:  Paolo Mannelli; Ashwin A Patkar; Kathi Peindl; David A Gorelick; Li-Tzy Wu; Edward Gottheil
Journal:  Addict Biol       Date:  2008-08-19       Impact factor: 4.280

10.  Neuropeptide trefoil factor 3 attenuates naloxone-precipitated withdrawal in morphine-dependent mice.

Authors:  Ping Wu; Hai-Shui Shi; Yi-Xiao Luo; Ruo-Xi Zhang; Jia-Li Li; Jie Shi; Lin Lu; Wei-Li Zhu
Journal:  Psychopharmacology (Berl)       Date:  2014-05-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.